Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer

  • The Phase 3 trial of Sanofi SA SNY and Regeneron Pharmaceuticals Inc's REGN Libtayo in combination with platinum-doublet chemotherapy was stopped early after meeting its overall survival (OS) primary endpoint in patients with advanced non-small-cell lung cancer (NSCLC). 
  • These data are planned to form the basis of regulatory submissions in the U.S. and European Union.
  • In this top-line initial analysis of 466 patients, combining Libtayo with chemotherapy reduced the risk of death by 29% compared to chemotherapy alone. 
  • Median OS was 22 months for Libtayo/chemo combo and 13 months for chemotherapy alone. 
  • No new Libtayo safety signals were identified.
  • Price Action: REGN shares are up 2.45 at $594.75, and SNY stock is up 1.1% at $50.45 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!